Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 27-35

  Audrito, Valentina ^a,b   Vaisitti, Tiziana ^a,b   Serra, Sara ^a,b   Bologna, Cinzia ^a,b   Brusa, Davide ^b   Malavasi, Fabio ^a   Deaglio, Silvia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Human Genetics Foundation (HuGeF)   (Italy)

Author keywords

CLL; Microenvironment; Survival signals; Targeted therapies

Indexed keywords

EID: 84868481268     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.012     Document Type: Review

References (124)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 352:804-815.
2. Zenz T., Mertens D., Kuppers R., Dohner H., Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 2010, 10:37-50.
3. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., Buchbinder A., Budman D., Dittmar K., Kolitz J., Lichtman S.M., Schulman P., Vinciguerra V.P., Rai K.R., Ferrarini M., Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
4. Malavasi F., Deaglio S., Damle R., Cutrona G., Ferrarini M., Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011.
5. Zucchetto A., Bomben R., Dal Bo M., Bulian P., Benedetti D., Nanni P., Del Poeta G., Degan M., Gattei V. CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia 2006, 20:523-525. author reply 528-529.
6. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., Marce S., Lopez-Guillermo A., Campo E., Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 2003, 348:1764-1775.
7. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., Dohner K., Bentz M., Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 2000, 343:1910-1916.
8. Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., Grunn A., Fangazio M., Capello D., Monti S., Cresta S., Gargiulo E., Forconi F., Guarini A., Arcaini L., Paulli M., Laurenti L., Larocca L.M., Marasca R., Gattei V., Oscier D., Bertoni F., Mullighan C.G., Foa R., Pasqualucci L., Rabadan R., Dalla-Favera R., Gaidano G. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 2011, 208:1389-1401.
9. Rossi D., Bruscaggin A., Spina V., Rasi S., Khiabanian H., Messina M., Fangazio M., Vaisitti T., Monti S., Chiaretti S., Guarini A., Del Giudice I., Cerri M., Cresta S., Deambrogi C., Gargiulo E., Gattei V., Forconi F., Bertoni F., Deaglio S., Rabadan R., Pasqualucci L., Foa R., Dalla-Favera R., Gaidano G. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011, 118:6904-6908.
10. Quesada V., Conde L., Villamor N., Ordonez G.R., Jares P., Bassaganyas L., Ramsay A.J., Bea S., Pinyol M., Martinez-Trillos A., Lopez-Guerra M., Colomer D., Navarro A., Baumann T., Aymerich M., Rozman M., Delgado J., Gine E., Hernandez J.M., Gonzalez-Diaz M., Puente D.A., Velasco G., Freije J.M., Tubio J.M., Royo R., Gelpi J.L., Orozco M., Pisano D.G., Zamora J., Vazquez M., Valencia A., Himmelbauer H., Bayes M., Heath S., Gut M., Gut I., Estivill X., Lopez-Guillermo A., Puente X.S., Campo E., Lopez-Otin C. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 2011, 44:47-52.
11. Rossi D., Fangazio M., Rasi S., Vaisitti T., Monti S., Cresta S., Chiaretti S., Del Giudice I., Fabbri G., Bruscaggin A., Spina V., Deambrogi C., Marinelli M., Fama R., Greco M., Daniele G., Forconi F., Gattei V., Bertoni F., Deaglio S., Pasqualucci L., Guarini A., Dalla-Favera R., Foa R., Gaidano G. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild type chronic lymphocytic leukemia. Blood 2012.
12. Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., Escaramis G., Jares P., Bea S., Gonzalez-Diaz M., Bassaganyas L., Baumann T., Juan M., Lopez-Guerra M., Colomer D., Tubio J.M., Lopez C., Navarro A., Tornador C., Aymerich M., Rozman M., Hernandez J.M., Puente D.A., Freije J.M., Velasco G., Gutierrez-Fernandez A., Costa D., Carrio A., Guijarro S., Enjuanes A., Hernandez L., Yague J., Nicolas P., Romeo-Casabona C.M., Himmelbauer H., Castillo E., Dohm J.C., de Sanjose S., Piris M.A., de Alava E., San Miguel J., Royo R., Gelpi J.L., Torrents D., Orozco M., Pisano D.G., Valencia A., Guigo R., Bayes M., Heath S., Gut M., Klatt P., Marshall J., Raine K., Stebbings L.A., Futreal P.A., Stratton M.R., Campbell P.J., Gut I., Lopez-Guillermo A., Estivill X., Montserrat E., Lopez-Otin C., Campo E. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
13. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
14. Deaglio S., Malavasi F. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica 2009, 94:752-756.
15. Fecteau J.F., Kipps T.J. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Frontiers Biosci. 2012, 4:61-73.
16. Dal-Bo M., Bertoni F., Forconi F., Zucchetto A., Bomben R., Marasca R., Deaglio S., Laurenti L., Efremov D.G., Gaidano G., Del Poeta G., Gattei V. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J. Trans. Med. 2009, 7:76.
17. Ghia P., Chiorazzi N., Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J. Intern. Med. 2008, 264:549-562.
18. Caligaris-Cappio F., Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?. J. Clin. Oncol. 2008, 26:4497-4503.
19. Munk Pedersen I., Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk. Lymphoma 2004, 45:2365-2372.
20. Pleyer L., Egle A., Hartmann T.N., Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat. Rev. Clin. Oncol. 2009, 6:405-418.
21. Faderl S., Ferrajoli A., Frankfurt O., Pettitt A. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia: Off. J. Leuk. Soc. Am., Leuk. Res. Fund, UK 2009, 23:457-466.
22. Nabhan C., Dalal N., Mehta J., Kay N.E. Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leuk. Lymphoma 2011, 52:374-386.
23. Papadimitriou C.S., Stein H., Lennert K. The complexity of immunohistochemical staining pattern of Hodgkin and Sternberg-reed cells-demonstration of immunoglobulin, albumin, alpha1-antichymotrypsin and lysozyme. Int. J. Cancer 1978, 21:531-541.
24. Soma L.A., Craig F.E., Swerdlow S.H. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum. Pathol. 2006, 37:152-159.
25. Ponzoni M., Doglioni C., Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. Semin. Diagn. Pathol. 2011, 28:161-166.
26. Ciccone M., Agostinelli C., Rigolin G.M., Piccaluga P.P., Cavazzini F., Righi S., Sista M.T., Sofritti O., Rizzotto L., Sabattini E., Fioritoni G., Falorio S., Stelitano C., Olivieri A., Attolico I., Brugiatelli M., Zinzani P.L., Saccenti E., Capello D., Negrini M., Cuneo A., Pileri S. Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. Leukemia: Offi. J. Leuk. Soc. Am., Leuk. Res. Fund, UK 2011.
27. Pileri S.A., Ascani S., Sabattini E., Fraternali-Orcioni G., Poggi S., Piccioli M., Piccaluga P.P., Gamberi B., Zinzani P.L., Leoncini L., Falini B. The pathologist's view point. Part I - Indolent lymphomas. Haematologica 2000, 85:1291-1307.
28. Chen H., Treweeke A.T., West D.C., Till K.J., Cawley J.C., Zuzel M., Toh C.H. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000, 96:3181-3187.
29. Molica S., Vacca A., Ribatti D., Cuneo A., Cavazzini F., Levato D., Vitelli G., Tucci L., Roccaro A.M., Dammacco F. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002, 100:3344-3351.
30. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br. J. Haematol. 2003, 123:380-388.
31. Rosati S., Kluin P.M. Chronic lymphocytic leukaemia: a review of the immuno-architecture. Curr. Top. Microbiol. Immunol. 2005, 294:91-107.
32. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., Freedman A., Inghirami G., Cro L., Baldini L., Neri A., Califano A., Dalla-Favera R. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 2001, 194:1625-1638.
33. Herishanu Y., Perez-Galan P., Liu D., Biancotto A., Pittaluga S., Vire B., Gibellini F., Njuguna N., Lee E., Stennett L., Raghavachari N., Liu P., McCoy J.P., Raffeld M., Stetler-Stevenson M., Yuan C., Sherry R., Arthur D.C., Maric I., White T., Marti G.E., Munson P., Wilson W.H., Wiestner A. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117:563-574.
34. Scielzo C., Ghia P., Conti A., Bachi A., Guida G., Geuna M., Alessio M., Caligaris-Cappio F. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J. Clin. Invest. 2005, 115:1644-1650.
35. Buchner M., Fuchs S., Prinz G., Pfeifer D., Bartholome K., Burger M., Chevalier N., Vallat L., Timmer J., Gribben J.G., Jumaa H., Veelken H., Dierks C., Zirlik K. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009, 69:5424-5432.
36. Ringshausen I., Schneller F., Bogner C., Hipp S., Duyster J., Peschel C., Decker T. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002, 100:3741-3748.
37. Muzio M., Apollonio B., Scielzo C., Frenquelli M., Vandoni I., Boussiotis V., Caligaris-Cappio F., Ghia P. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008, 112:188-195.
38. Hewamana S., Alghazal S., Lin T.T., Clement M., Jenkins C., Guzman M.L., Jordan C.T., Neelakantan S., Crooks P.A., Burnett A.K., Pratt G., Fegan C., Rowntree C., Brennan P., Pepper C. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008, 111:4681-4689.
39. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
40. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., Belhoul L., Stella S., Stavroyianni N., Crespo M., Hadzidimitriou A., Sutton L., Bosch F., Laoutaris N., Anagnostopoulos A., Montserrat E., Fassas A., Dighiero G., Caligaris-Cappio F., Merle-Beral H., Ghia P., Davi F. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
41. Davids M.S., Brown J.R. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk. Lymphoma 2012.
42. Woyach J.A., Johnson A.J., Byrd J.C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012.
43. Wekerle H., Ketelsen U.P. Thymic nurse cells-Ia-bearing epithelium involved in T-lymphocyte differentiation?. Nature 1980, 283:402-404.
44. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
45. Nishio M., Endo T., Tsukada N., Ohata J., Kitada S., Reed J.C., Zvaifler N.J., Kipps T.J. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005, 106:1012-1020.
46. Deaglio S., Vaisitti T., Bergui L., Bonello L., Horenstein A.L., Tamagnone L., Boumsell L., Malavasi F. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005, 105:3042-3050.
47. Tsukada N., Burger J.A., Zvaifler N.J., Kipps T.J. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030-1037.
48. Ferretti E., Bertolotto M., Deaglio S., Tripodo C., Ribatti D., Audrito V., Blengio F., Matis S., Zupo S., Rossi D., Ottonello L., Gaidano G., Malavasi F., Pistoia V., Corcione A. A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia: Offi. J. Leuk. Soc. Am., Leuk. Res. Fund, UK 2011, 25:1268-1277.
49. Burger J.A., Quiroga M.P., Hartmann E., Burkle A., Wierda W.G., Keating M.J., Rosenwald A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
50. Zucchetto A., Benedetti D., Tripodo C., Bomben R., Dal Bo M., Marconi D., Bossi F., Lorenzon D., Degan M., Rossi F.M., Rossi D., Bulian P., Franco V., Del Poeta G., Deaglio S., Gaidano G., Tedesco F., Malavasi F., Gattei V. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009, 69:4001-4009.
51. Gensicke H., Leppert D., Yaldizli O., Lindberg R.L., Mehling M., Kappos L., Kuhle J. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs 2012, 26:11-37.
52. Targan S.R., Feagan B.G., Fedorak R.N., Lashner B.A., Panaccione R., Present D.H., Spehlmann M.E., Rutgeerts P.J., Tulassay Z., Volfova M., Wolf D.C., Hernandez C., Bornstein J., Sandborn W.J. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007, 132:1672-1683.
53. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
54. Ding W., Nowakowski G.S., Knox T.R., Boysen J.C., Maas M.L., Schwager S.M., Wu W., Wellik L.E., Dietz A.B., Ghosh A.K., Secreto C.R., Medina K.L., Shanafelt T.D., Zent C.S., Call T.G., Kay N.E. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br. J. Haematol. 2009, 147:471-483.
55. Ding W., Knox T.R., Tschumper R.C., Wu W., Schwager S.M., Boysen J.C., Jelinek D.F., Kay N.E. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010, 116:2984-2993.
56. Baeriswyl V., Christofori G. The angiogenic switch in carcinogenesis. Semin. Cancer Biol. 2009, 19:329-337.
57. Paesler J., Gehrke I., Gandhirajan R.K., Filipovich A., Hertweck M., Erdfelder F., Uhrmacher S., Poll-Wolbeck S.J., Hallek M., Kreuzer K.A. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin. Cancer Res.: Offi J. Am. Assoc. Cancer Res. 2010, 16:3390-3398.
58. Pedersen I.M., Kitada S., Leoni L.M., Zapata J.M., Karras J.G., Tsukada N., Kipps T.J., Choi Y.S., Bennett F., Reed J.C. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100:1795-1801.
59. + B lymphocytes. Blood 2003, 101:1962-1969.
60. Cuni S., Perez-Aciego P., Perez-Chacon G., Vargas J.A., Sanchez A., Martin-Saavedra F.M., Ballester S., Garcia-Marco J., Jorda J., Durantez A. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia: Offi J. Leuk. Soc. Am., Leuk. Res. Fund, UK 2004, 18:1391-1400.
61. Edelmann J., Klein-Hitpass L., Carpinteiro A., Fuhrer A., Sellmann L., Stilgenbauer S., Duhrsen U., Durig J. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk. Res. 2008, 32:1565-1572.
62. Barata J.T. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv. Enzyme Regul. 2011, 51:37-49.
63. Jou S.T., Carpino N., Takahashi Y., Piekorz R., Chao J.R., Wang D., Ihle J.N. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol. 2002, 22:8580-8591.
64. Lannutti B.J., Meadows S.A., Herman S.E., Kashishian A., Steiner B., Johnson A.J., Byrd J.C., Tyner J.W., Loriaux M.M., Deininger M., Druker B.J., Puri K.D., Ulrich R.G., Giese N.A. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117:591-594.
65. Hallek M. Therapy of chronic lymphocytic leukaemia. Best Practice Res. Clin. Haematol. 2010, 23:85-96.
66. Niedermeier M., Hennessy B.T., Knight Z.A., Henneberg M., Hu J., Kurtova A.V., Wierda W.G., Keating M.J., Shokat K.M., Burger J.A. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009, 113:5549-5557.
67. Buggins A.G., Pepper C., Patten P.E., Hewamana S., Gohil S., Moorhead J., Folarin N., Yallop D., Thomas N.S., Mufti G.J., Fegan C., Devereux S. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res. 2010, 70:7523-7533.
68. Hewamana S., Lin T.T., Jenkins C., Burnett A.K., Jordan C.T., Fegan C., Brennan P., Rowntree C., Pepper C. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin. Cancer Res.: Offi. J. Am. Assoc. Cancer Res. 2008, 14:8102-8111.
69. Catovsky D., Lauria F., Matutes E., Foa R., Mantovani V., Tura S., Galton D.A. Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia. II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia. Br. J. Haematol. 1981, 47:539-544.
70. + T cell subsets in chronic lymphocytic leukemia. J. Immunol. 1997, 158:1482-1489.
71. Rezvany M.R., Jeddi-Tehrani M., Wigzell H., Osterborg A., Mellstedt H. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood 2003, 101:1063-1070.
72. D'Arena G., Laurenti L., Minervini M.M., Deaglio S., Bonello L., De Martino L., De Padua L., Savino L., Tarnani M., De Feo V., Cascavilla N. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk. Res. 2011, 35:363-368.
73. Gonzalez-Rodriguez A.P., Contesti J., Huergo-Zapico L., Lopez-Soto A., Fernandez-Guizan A., Acebes-Huerta A., Gonzalez-Huerta A.J., Gonzalez E., Fernandez-Alvarez C., Gonzalez S. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk. Lymphoma 2010, 51:1829-1836.
74. + T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J. Immunother. 2009, 32:302-309.
75. Patten P.E., Buggins A.G., Richards J., Wotherspoon A., Salisbury J., Mufti G.J., Hamblin T.J., Devereux S. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008, 111:5173-5181.
76. Borge M., Nannini P.R., Galletti J.G., Morande P.E., Avalos J.S., Bezares R.F., Giordano M., Gamberale R. CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia. Haematologica 2010, 95:768-775.
77. Plander M., Seegers S., Ugocsai P., Diermeier-Daucher S., Ivanyi J., Schmitz G., Hofstadter F., Schwarz S., Orso E., Knuchel R., Brockhoff G. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia: Offi. J. Leuk. Soc. Am., Leuk. Res. Fund, UK 2009, 23:2118-2128.
78. Granziero L., Ghia P., Circosta P., Gottardi D., Strola G., Geuna M., Montagna L., Piccoli P., Chilosi M., Caligaris-Cappio F. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001, 97:2777-2783.
79. Vogler M., Butterworth M., Majid A., Walewska R.J., Sun X.M., Dyer M.J., Cohen G.M. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009, 113:4403-4413.
80. Byrd J.C., Kipps T.J., Flinn I.W., Cooper M., Odenike O., Bendiske J., Rediske J., Bilic S., Dey J., Baeck J., O'Brien S. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leukemia and Lymphoma 2012.
81. Luqman M., Klabunde S., Lin K., Georgakis G.V., Cherukuri A., Holash J., Goldbeck C., Xu X., Kadel E.E., Lee S.H., Aukerman S.L., Jallal B., Aziz N., Weng W.K., Wierda W., O'Brien S., Younes A. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008, 112:711-720.
82. Ramsay A.G., Johnson A.J., Lee A.M., Gorgun G., Le Dieu R., Blum W., Byrd J.C., Gribben J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 2008, 118:2427-2437.
83. Riches J.C., Ramsay A.G., Gribben J.G. T-cell function in chronic lymphocytic leukaemia. Semin. Cancer Biol. 2010, 20:431-438.
84. + T cells. Clin. Exp. Immunol. 2011, 166:154-163.
85. Riches J.C., Ramsay A.G., Gribben J.G. Immune reconstitution in chronic lymphocytic leukemia. Curr. Hematol. Malignancy Rep. 2012.
86. Anderson K.C. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin. Hematol. 2005, 42:S3-8.
87. Chen C.I., Bergsagel P.L., Paul H., Xu W., Lau A., Dave N., Kukreti V., Wei E., Leung-Hagesteijn C., Li Z.H., Brandwein J., Pantoja M., Johnston J., Gibson S., Hernandez T., Spaner D., Trudel S. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J. Clin. Oncol.: Offi J. Am. Soc. Clin. Oncol. 2011, 29:1175-1181.
88. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000, 96:2917-2924.
89. Lapalombella R., Andritsos L., Liu Q., May S.E., Browning R., Pham L.V., Blum K.A., Blum W., Ramanunni A., Raymond C.A., Smith L.L., Lehman A., Mo X., Jarjoura D., Chen C.S., Ford R., Rader C., Muthusamy N., Johnson A.J., Byrd J.C. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010, 115:2619-2629.
90. Urba W.J., Longo D.L. Redirecting T cells. N. Engl. J. Med. 2011, 365:754-757.
91. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
92. Souza-Moreira L., Campos-Salinas J., Caro M., Gonzalez-Rey E. Neuropeptides as pleiotropic modulators of the immune response. Neuroendocrinology 2011, 94:89-100.
93. Smit L.A., Hallaert D.Y., Spijker R., de Goeij B., Jaspers A., Kater A.P., van Oers M.H., van Noesel C.J., Eldering E. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007, 109:1660-1668.
94. Stagg J., Divisekera U., McLaughlin N., Sharkey J., Pommey S., Denoyer D., Dwyer K.M., Smyth M.J. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 2010, 107:1547-1552.
95. Hauser R.A., Cantillon M., Pourcher E., Micheli F., Mok V., Onofrj M., Huyck S., Wolski K. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011, 10:221-229.
96. Audrito V., Vaisitti T., Rossi D., Gottardi D., D'Arena G., Laurenti L., Gaidano G., Malavasi F., Deaglio S. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 2011.
97. Cea M., Soncini D., Fruscione F., Raffaghello L., Garuti A., Emionite L., Moran E., Magnone M., Zoppoli G., Reverberi D., Caffa I., Salis A., Cagnetta A., Bergamaschi M., Casciaro S., Pierri I., Damonte G., Ansaldi F., Gobbi M., Pistoia V., Ballestrero A., Patrone F., Bruzzone S., Nencioni A. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One 2011, 6:e22739.
98. Colmone A., Amorim M., Pontier A.L., Wang S., Jablonski E., Sipkins D.A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322:1861-1865.
99. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
100. Carman C.V. Mechanisms for transcellular diapedesis: probing and pathfinding by 'invadosome-like protrusions'. J. Cell Sci. 2009, 122:3025-3035.
101. Burger J.A., Kipps T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
102. Richardson S.J., Matthews C., Catherwood M.A., Alexander H.D., Carey B.S., Farrugia J., Gardiner A., Mould S., Oscier D., Copplestone J.A., Prentice A.G. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107:3584-3592.
103. Deaglio S., Vaisitti T., Aydin S., Bergui L., D'Arena G., Bonello L., Omede P., Scatolini M., Jaksic O., Chiorino G., Efremov D., Malavasi F. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007, 110:4012-4021.
104. Vaisitti T., Aydin S., Rossi D., Cottino F., Bergui L., D'Arena G., Bonello L., Horenstein A.L., Brennan P., Pepper C., Gaidano G., Malavasi F., Deaglio S. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010, 24:958-969.
105. Calandra G., Bridger G., Fricker S. CXCR4 in clinical hematology. Curr. Top. Microbiol. Immunol. 2010, 341:173-191.
106. S O.B. Advances in CLL. Clin. Adv. Hematol. Oncol.: H&O 2007, 5:23-25.
107. Ye F., Kim C., Ginsberg M.H. Reconstruction of integrin activation. Blood 2012, 119:26-33.
108. Gattei V., Bulian P., Del Principe M.I., Zucchetto A., Maurillo L., Buccisano F., Bomben R., Dal-Bo M., Luciano F., Rossi F.M., Degan M., Amadori S., Del Poeta G. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008, 111:865-873.
109. Redondo-Munoz J., Escobar-Diaz E., Samaniego R., Terol M.J., Garcia-Marco J.A., Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006, 108:3143-3151.
110. Zucchetto A., Vaisitti T., Benedetti D., Tissino E., Bertagnolo V., Rossi D., Bomben R., Dal Bo M., Del Principe M.I., Gorgone A., Pozzato G., Gaidano G., Del Poeta G., Malavasi F., Deaglio S., Gattei V. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia: Offi. J. Leuk. Soc. Am., Leuk. Res. Fund, UK 2012.
111. Ilangumaran S., Borisch B., Hoessli D.C. Signal transduction via CD44: role of plasma membrane microdomains. Leuk. Lymphoma 1999, 35:455-469.
112. Shi X., Leng L., Wang T., Wang W., Du X., Li J., McDonald C., Chen Z., Murphy J.W., Lolis E., Noble P., Knudson W., Bucala R. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006, 25:595-606.
113. Gore Y., Starlets D., Maharshak N., Becker-Herman S., Kaneyuki U., Leng L., Bucala R., Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J. Biol. Chem. 2008, 283:2784-2792.
114. Gordin M., Tesio M., Cohen S., Gore Y., Lantner F., Leng L., Bucala R., Shachar I. c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J. Immunol. 2010.
115. Stein R., Mattes M.J., Cardillo T.M., Hansen H.J., Chang C.H., Burton J., Govindan S., Goldenberg D.M. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin. Cancer Res.: Offi J. Am. Assoc. Cancer Res. 2007, 13:5556s-5563s.
116. Hertlein E., Triantafillou G., Sass E.J., Hessler J.D., Zhang X., Jarjoura D., Lucas D.M., Muthusamy N., Goldenberg D.M., Lee R.J., Byrd J.C. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010, 116:2554-2558.
117. de la Fuente M.T., Casanova B., Moyano J.V., Garcia-Gila M., Sanz L., Garcia-Marco J., Silva A., Garcia-Pardo A. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J. Leuk. Biol. 2002, 71:495-502.
118. Hua H., Li M., Luo T., Yin Y., Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell. Mol. Life Sci.: CMLS 2011, 68:3853-3868.
119. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278:16-27.
120. Molica S., Vitelli G., Levato D., Giannarelli D., Vacca A., Cuneo A., Cavazzini F., Squillace R., Mirabelli R., Digiesi G. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur. J. Haematol. 2003, 70:373-378.
121. Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., Van den Steen P.E., Hernandez del Cerro M., Roderfeld M., Roeb E., Opdenakker G., Garcia-Marco J.A., Garcia-Pardo A. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010, 17:160-172.
122. Buggins A.G., Levi A., Gohil S., Fishlock K., Patten P.E., Calle Y., Yallop D., Devereux S. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br. J. Haematol. 2011.
123. van der Veer M.S., de Weers M., van Kessel B., Bakker J.M., Wittebol S., Parren P.W., Lokhorst H.M., Mutis T. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011, 96:284-290.
124. Deaglio S., Aydin S., Vaisitti T., Bergui L., Malavasi F. CD38 at the junction between prognostic marker and therapeutic target. Trends Mol. Med. 2008, 14:210-218.